Vanda Pharmaceuticals (VNDA) said Monday that it submitted a new drug application with the US Food and Drug Administration requesting marketing approval for Bysanti to treat acute bipolar I disorder and schizophrenia.
The company started a phase 3 study of the drug as a once-daily add-on treatment for major depressive order in Q4, with results expected in 2026.
Shares of the company were down 2.1% in recent trading.
Price: 4.59, Change: -0.10, Percent Change: -2.13
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。